Table 4.
Treatments | Injury duration | Reperfusion duration | Death type | Assessment | Critical protein | Reference |
---|---|---|---|---|---|---|
OGD/R | 12 h | 1 h | Pyroptosis | Hoechst 33342, PI, CCK-8 | NLRP3, C-CASP-1, GSDMD-N | Zeng et al., 2020 |
OGD/R | 2 h | 2 h | Pyroptosis | MTT, LDH, TUNEL | CASP-1, CASP-1p20, GSDMD, GSDMD-N | Li et al., 2021b |
OGD/R | 12 h | 4 h | Pyroptosis | MTT, TEM | NLRP3, ASC, C-CASP-1, GSDMD, GSDMD-N | Liu et al., 2021a |
OGD | 2, 4, 8, 12, 24 h | 0 | Apoptosis | MTT | C-CASP-3, Bcl-2, Bax | Lin et al., 2015 |
OGD | 12 h | 0 | Apoptosis | Hoechst 33342, MTT, Flow cytometry | C-CASP-3, CASP-12, Bcl-2 | Cao et al., 2016 |
OGD/R | 0, 2, 4 h | 24 h | Apoptosis | TUNEL, CCK-8 | Bcl-2, Bax | Ren et al., 2019 |
OGD | 8 h | 0 | Necroptosis | PI (Nec-1) | RIP1, RIP3, MLKL | Wang et al., 2018 |
H/R | 8 h | 24 h | Necroptosis | LDH, Flow cytometry | RIP1, RIP3, MLKL/p-MLKL | Zhang et al., 2019b |
ASC: Apoptosis-associated speck-like protein containing a caspase recruit domain; Bax: B-cell lymphoma 2-associated X; Bcl-2: B-cell lymphoma 2; CASP: cysteinyl aspartate-specific protease; C-CASP: cleaved CASP; CCK-8: cell counting kit-8; C-GSDMD: cleaved GSDMD; GSDMD: gasdermin D; GSDMD-N: N-terminal domain of gasdermin D; H/R: Hypoxia/reoxygenation; IL: interleukin; LDH: lactate dehydrogenase; MLKL: mixed lineage kinase domain-like pseudokinase; MTT: methylthiazolyldiphenyl-tetrazolium bromide; Nec-1: Necrostatin-1; NLRP: nucleotide-binding domain and leucine-rich repeat pyrin-domain containing protein; OGD: oxygen and glucose deprivation; OGD/R: OGD/recovery; PI: propidium iodide staining; PI (Nec-1): Nec-1 inhibited necroptosis, and after the addition of Nec-1, PI staining was performed to verify the occurrence of necroptosis by comparing with the control group; p-MLKL: phosphorylation of MLKL; RIP: receptorinteracting protein kinase; SD rats: Sprague-Dawley rats; TEM: transmission electron microscope; TUNEL: TdT-mediated dUTP nick-end labeling.